<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title>PLoS Neglected Tropical Diseases</journal-title><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PNTD-RA-0331R2</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0000375</article-id><article-id pub-id-type="pmid">19190772</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology</subject><subject>Immunology/Genetics of the Immune System</subject><subject>Immunology/Immunity to Infections</subject></subj-group></article-categories><title-group><article-title>Association of the Gene Polymorphisms IFN-&#x003b3; &#x0002b;874, IL-13 &#x02212;1055 and IL-4 &#x02212;590 with Patterns of Reinfection with <italic>Schistosoma mansoni</italic></article-title><alt-title alt-title-type="running-head">Cytokine Genes and Schistosomiasis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gatlin</surname><given-names>Michael R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Black</surname><given-names>Carla L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mwinzi</surname><given-names>Pauline N.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Secor</surname><given-names>W. Evan</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karanja</surname><given-names>Diana M.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Colley</surname><given-names>Daniel G.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>University of Georgia, Athens, Georgia, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Kenya Medical Research Institute, Kisumu, Kenya</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>King</surname><given-names>Charles H.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Case Western Reserve University School of Medicine, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>dcolley@uga.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: MRG WES DMK DGC. Performed the experiments: MRG. Analyzed the data: MRG CLB DGC. Contributed reagents/materials/analysis tools: PNM WES DMK DGC. Wrote the paper: MRG. Oraganized and implemented longitudinal field work: PNM DMK.</p></fn></author-notes><pub-date pub-type="collection"><month>2</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>10</day><month>2</month><year>2009</year></pub-date><volume>3</volume><issue>2</issue><elocation-id>e375</elocation-id><history><date date-type="received"><day>15</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2009</year></date></history><copyright-statement>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>The immunologic findings that most consistently correlate with resistance in human schistosomiasis are high levels of IgE and low levels of IgG4. We have genotyped gene and promoter polymorphisms of cytokines associated with regulation of these isotypes in a cohort of men occupationally exposed to <italic>Schistosoma mansoni</italic> in western Kenya and evaluated their patterns with respect to resistance and susceptibility to reinfection after treatment and cure with praziquantel (PZQ).</p></sec><sec><title>Methodology/Principal Findings</title><p>In this cohort, polymorphisms in IL-4 (&#x02212;590T high IgE), IL-13 (&#x02212;1055T high producer) and IFN-&#x003b3; (&#x0002b;874A high producer) demonstrated several correlations with resistance to reinfection. Resistance to reinfection was significantly correlated with the heterozygous IL-4 &#x02212;590 genotype C/T (OR 3.5, &#x0005b;CI 1.2, 10.2&#x0005d;) compared to T/T. Among men with a homozygous IL-13 genotype CC/TT, having a T allele at the IFN-&#x003b3; &#x0002b;874 position increased the odds of resistance relative to individuals with the IFN-&#x003b3; &#x0002b;874 A/A genotype (OR&#x0200a;&#x0003d;&#x0200a;17.5 &#x0005b;CI 3.0, 101.5&#x0005d;). Among men with homozygous A/A IFN-&#x003b3; genotype, the heterozygous IL-13 genotype C/T was associated with resistance relative to the homozygous C/C or T/T genotypes (OR&#x0200a;&#x0003d;&#x0200a;22.5 &#x0005b;CI 3.5, 144.4&#x0005d;). No increases in odds of resistance were found in relation to the IL-13 genotype among those with a T allele in the IFN-&#x003b3; gene or in relation to the IFN-&#x003b3; genotype among those with a heterozygous IL-13 genotype. Calculation of the attributable proportion of resistance showed a significant synergistic interaction between IL-13 &#x02212;1055 C/T and IL-4 &#x02212;590 C/T.</p></sec><sec><title>Conclusions</title><p>The identified polymorphisms do not by themselves confer resistance or susceptibility, but we propose that these genotypes allow the resistant phenotype to be developed and expressed upon suitable immune exposure. Based on the literature, these polymorphisms contribute to the regulation of their respective cytokines, likely leading to downstream differences in the production and interrelationships of critical defense mechanisms.</p></sec></abstract><abstract abstract-type="summary"><title>Author Summary</title><p>Approximately 200 million people have schistosomiasis in parts of Africa, South America, the Middle East, the Caribbean and Asia. Several studies of multiple treatments and reinfections indicate that some people develop resistance to reinfection. Of all the immunologic findings associated with such studies, the most consistent observation is that resistance (usually defined as lower levels of infection upon reinfection) correlates with high IgE and low IgG4 antibodies against schistosome antigens. Our studies test whether single nucleotide polymorphisms residing in the gene or promoter regions of cytokines pivotal in controlling production of these antibody isotypes are different amongst those that develop resistance to reinfection as opposed to those that do not. Through genotyping of these polymorphisms in a cohort of occupationally exposed car washers, we found that men with certain genotypic patterns of polymorphisms in IL-4, IFN-&#x003b3;, and IL-13 were significantly more likely to be resistant to reinfection than those with different patterns. These data provide initial insights into the potential genetic foundation of propensities of people to develop resistance to reinfection by schistosomes, and offer a basis for further molecular studies of how these polymorphisms might work at the transcriptional and gene product level in cells stimulated by schistosome antigens.</p></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>There have been many studies of resistance to schistosome infections in humans following treatment and reinfection. Such studies involve documentation of cases of schistosomiasis, their treatment and cure, and examinations at a later date to see if reinfections occurred <xref ref-type="bibr" rid="pntd.0000375-Butterworth1">&#x0005b;1&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Dunne1">&#x0005b;2&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Li1">&#x0005b;3&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Wilkins1">&#x0005b;4&#x0005d;</xref>. Of all the immunologic findings associated with these investigations, the most consistent observation is that resistance (usually defined as lower levels of infection) correlates with high IgE and low IgG4 antibodies against schistosome antigens <xref ref-type="bibr" rid="pntd.0000375-Caldas1">&#x0005b;5&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Demeure1">&#x0005b;6&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Gomes1">&#x0005b;7&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Gounni1">&#x0005b;8&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Grogan1">&#x0005b;9&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Grogan2">&#x0005b;10&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Hagan1">&#x0005b;11&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Li2">&#x0005b;12&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Rihet1">&#x0005b;13&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Satti1">&#x0005b;14&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-vanDerKleij1">&#x0005b;15&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Webster1">&#x0005b;16&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Webster2">&#x0005b;17&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Zhang1">&#x0005b;18&#x0005d;</xref>. Other studies have reported that production of IFN-&#x003b3; and IL-5 to schistosome antigens are also correlated with resistance <xref ref-type="bibr" rid="pntd.0000375-Brito1">&#x0005b;19&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-ElRidi1">&#x0005b;20&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-RibeirodeJesus1">&#x0005b;21&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Viana1">&#x0005b;22&#x0005d;</xref>.</p><p>A genetic region (SM1) has been identified that shows a strong positive correlation to the level of infection in humans <xref ref-type="bibr" rid="pntd.0000375-Dessein1">&#x0005b;23&#x0005d;</xref>. SM1 maps to chromosome 5 in the 5q31&#x02013;q33 region that contains several genes associated with immune responses <xref ref-type="bibr" rid="pntd.0000375-Marquet1">&#x0005b;24&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Marquet2">&#x0005b;25&#x0005d;</xref>. These genes code for proteins that are associated with the regulation of Th2-type responses such as IL-3, IL-4, IL-5, IL-9, and IL-13 and IgE. Polymorphisms in these cytokines that lead to an increase or decrease in cytokine levels could influence the antibody isotypes and cellular interactions that in turn may contribute to resistance or susceptibility of individuals to reinfection with schistosomiasis.</p><p>There have been contradictory reports on the effect the IL-4 &#x02212;590 C/T (rs 2243250) polymorphism has on IgE levels in different settings. One group found that infants with a IL-4 &#x02212;590 C allele had a higher risk of elevated IgE in their cord blood <xref ref-type="bibr" rid="pntd.0000375-Wen1">&#x0005b;26&#x0005d;</xref>. However, it was also reported that total IgE levels were significantly elevated in children with severe malaria carrying the &#x02212;590T allele <xref ref-type="bibr" rid="pntd.0000375-Verra1">&#x0005b;27&#x0005d;</xref>. It is well known that IL-4 plays an important role in IgE class switching <xref ref-type="bibr" rid="pntd.0000375-Bacharier1">&#x0005b;28&#x0005d;</xref> and reports that the &#x02212;590 C/T polymorphism are associated with differing amounts of IgE made it a candidate for this study.</p><p>Kouriba, et al. reported that IL-13 &#x02212;1055C (rs 1800925) and &#x02212;591A (rs 2069743) were associated with the upper 10&#x00025; infection levels in individuals infected with <italic>S. haematobium</italic> (susceptibility) <xref ref-type="bibr" rid="pntd.0000375-Kouriba1">&#x0005b;29&#x0005d;</xref>. Van der Pouw Kraan et al. described an NF-AT binding site at IL-13 -1055 that showed increased binding of nuclear proteins with the T allele <xref ref-type="bibr" rid="pntd.0000375-vanderPouwKraan1">&#x0005b;30&#x0005d;</xref>. Furthermore, it was reported that transcription of the IL-13 -1055T allele was enhanced in Th2 polarized CD4&#x0002b; cells, but not in nonpolarized (i.e., Th0) CD4&#x0002b; T cells <xref ref-type="bibr" rid="pntd.0000375-Cameron1">&#x0005b;31&#x0005d;</xref>. Thus, the IL-13-1055 polymorphism, and possibly &#x02212;591, could be important in resistance to <italic>S. mansoni</italic>. The R130Q SNP (G/A) (rs 20541) in IL-13 causes a replacement of arginine with glutamine in &#x003b1; helix D, a region involved in IL-13 interactions with IL-13 receptors <xref ref-type="bibr" rid="pntd.0000375-Vladich1">&#x0005b;32&#x0005d;</xref>. The glutamine variant has been associated with increased levels of total serum IgE <xref ref-type="bibr" rid="pntd.0000375-Graves1">&#x0005b;33&#x0005d;</xref> and atopy <xref ref-type="bibr" rid="pntd.0000375-He1">&#x0005b;34&#x0005d;</xref>. It has also been shown that soluble IL-13R&#x003b1;2 (an IL-13 decoy receptor) neutralizes the arginine variant more effectively than the glutamine variant <xref ref-type="bibr" rid="pntd.0000375-Vladich1">&#x0005b;32&#x0005d;</xref>. This may suggest a possible feedback mechanism that could account for increased total serum IgE in the glutamine variant.</p><p>While most studies have found that Th2 responses are associated with resistance to reinfection with schistosomiasis, other studies found that IFN-&#x003b3; production correlates to resistance <xref ref-type="bibr" rid="pntd.0000375-Brito1">&#x0005b;19&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-ElRidi1">&#x0005b;20&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-RibeirodeJesus1">&#x0005b;21&#x0005d;</xref>. Pravica et al. showed that the &#x0002b;874T (rs 2430561) allele corresponds with high production of IFN-&#x003b3; and that the A/T site coincides with a putative NF-kappa B binding site <xref ref-type="bibr" rid="pntd.0000375-Pravica1">&#x0005b;35&#x0005d;</xref>. These studies prompted us to include the IFN-&#x003b3; &#x0002b;874 polymorphism in our study.</p><p>IL-10 has been shown to influence IgE and IgG4 production <xref ref-type="bibr" rid="pntd.0000375-Akdis1">&#x0005b;36&#x0005d;</xref>. Differential production of IL-10 has been shown to be associated with different allelic variants of the IL-10 promoter (&#x02212;1082 A/G &#x0005b;rs 1800896&#x0005d;, &#x02212;819 T/C &#x0005b;rs 1800871&#x0005d;, and &#x02212;592 A/C &#x0005b;rs 1800872&#x0005d;). The different haplotypes that have been associated with production of IL-10 are as follows: &#x0201c;high&#x0201d; IL-10 producer haplotype (GCC/GCC), &#x0201c;intermediate&#x0201d; producer haplotypes (GCC/ACC, GCC/ATA), and &#x0201c;low&#x0201d; producer haplotypes (ATA/ATA, ACC/ATA, ACC/ACC) <xref ref-type="bibr" rid="pntd.0000375-EdwardsSmith1">&#x0005b;37&#x0005d;</xref>. Indeed, the ATA/ATA haplotype has been associated with increased eosinophil counts and circulating IgE in adult asthma when compared to the other possible haplotypes <xref ref-type="bibr" rid="pntd.0000375-Karjalainen1">&#x0005b;38&#x0005d;</xref>. However, the group that first described these polymorphisms conclude that high IL-10 production was dependant on having a G in the &#x02212;1082 position independent of the &#x02212;819 and &#x02212;592 polymorphisms <xref ref-type="bibr" rid="pntd.0000375-Turner1">&#x0005b;39&#x0005d;</xref>. Furthermore, Ruess et al. has shown that &#x02212;1082A binds PU.1, which can inhibit gene transcription.</p><p>Based on these and other studies, we examined possible relationships between single nucleotide polymorphisms in the IL-4 (&#x02212;590 C/T), IL-13&#x0005b;(&#x02212;1055 C/T), (&#x02212;591A/G), (R130Q G/A)&#x0005d;, IL-10 (&#x02212;1082 A/G; &#x02212;819 C/T; &#x02212;592 C/A), and IFN-&#x003b3; (&#x0002b;874A/T) genes or promoters in relation to resistance and susceptibility to schistosomiasis of a cohort of occupationally exposed adult men many of whom we have studied longitudinally for as long as 12 years <xref ref-type="bibr" rid="pntd.0000375-Karanja1">&#x0005b;40&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Mwinzi1">&#x0005b;41&#x0005d;</xref>.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Study participants</title><p>The field site for this study was the western Kenyan city of Kisumu on the shores of Lake Victoria. <italic>S. mansoni</italic>-infected <italic>Biomphalaria sudanica</italic> snails have been identified (data unpublished) in the area around the exposure site. The study participants were all car washers occupationally exposed to <italic>S. mansoni</italic> as they stood in Lake Victoria, using its waters to wash cars driven into the shallow areas of the lake. This study was performed on a total of 87 car washers (all adult men). However, it was not possible to use all data from every individual in every analysis; some epidemiologic data regarding infections, cures or reinfections were insufficient or incomplete.</p><p>This investigation was approved by the Institutional Review Boards of the University of Georgia and the Centers for Diseases Control and Prevention, the Scientific Steering Committee of the Kenya Medical Research Institute (KEMRI), and the National Ethics Review Committee of Kenya. After obtaining written informed consent and enrolling the participants, we examined their stools for <italic>S. mansoni</italic> eggs and for other helminth ova by the modified Kato-Katz method (Vestergaard-Frandsen, Denmark). In most instances, this involved 2 slides per stool specimen from 3 stool specimens over a one week period. The participants who were positive for <italic>S. mansoni</italic> were treated with 40 mg/kg praziquantel (PZQ); men positive for other soil-transmitted helminth eggs were treated with 400 mg albendazole. Individuals' stools were checked 6 weeks after treatment and the men were retreated if still egg positive. Upon becoming egg negative, they were then followed by stool examination every 4 weeks to determine their time to reinfection as a means of determining their relative resistance to reinfection (see below).</p></sec><sec id="s2b"><title>DNA preparation</title><p>White blood cell-containing buffy coats were separated using the Ficoll-hypaque technique from blood obtained for immunological assays. The buffy coats were stored at &#x02212;20&#x000b0;C and DNA was isolated at KEMRI/CGHR laboratories using the Wizard&#x000ae; Genomic DNA Purification Kit from Promega. DNA from 300 &#x000b5;l of buffy coat for each car washer was isolated per the manufacturer's instructions. Dried DNA pellets were then transported to Athens, Georgia, USA for genotyping.</p></sec><sec id="s2c"><title>PCR reactions</title><p>PCR reactions of IL-13 and IL-4 SNPs were performed on a PTC-200 DNA Engine from MJ Research. PCR of the IL-13 &#x02212;1055 C/T was conducted in a 50 &#x000b5;l reaction containing 100 ng DNA, 5 &#x000b5;l of 1&#x000d7; Qiagen PCR buffer, 0.5 &#x000b5;M of each dNTP, 0.4 &#x000b5;M of each primer, 1 mM MgCl<sub>2</sub>, and 2.5 U of <italic>Taq</italic> polymerase (Qiagen). The following sequences were used: forward primer, <named-content content-type="gene">5&#x02032;-ATGCCTTGTGAGGAGGGTCAC</named-content>; reverse primer, <named-content content-type="gene">5&#x02032;-CCAGTCTCTGCAGGATCAACC</named-content><xref ref-type="bibr" rid="pntd.0000375-Howard1">&#x0005b;42&#x0005d;</xref>. Initial denaturation was performed at 95&#x000b0;C for 3 min followed by 30 cycles of PCR with the following conditions: 95&#x000b0;C for 30 sec, 62&#x000b0;C for 30 sec for annealing, 72&#x000b0;C for 1 min, and a final 72&#x000b0;C for 3 min. PCR of the IL-13 &#x02212;591 A/G was conducted in a 50 &#x000b5;l reaction containing 100 ng DNA, 5 &#x000b5;l of 1&#x000d7; Qiagen PCR buffer, 0.5 &#x000b5;M of each dNTP, 0.4 &#x000b5;M of each primer, 3 mM MgCl<sub>2</sub>, and 2.5 U of <italic>Taq</italic> polymerase (Qiagen). Initial denaturation was performed at 94&#x000b0;C for 5 min followed by 34 cycles of PCR with the following conditions: 94&#x000b0;C for 1 min, 61&#x000b0;C for 45 sec for annealing, 72&#x000b0;C for 45 sec, and a final 72&#x000b0;C for 3 min. The following sequences were used: forward primer, <named-content content-type="gene">5&#x02032;-CCAGCCTGGCCCAGTTAAGAGTTT</named-content>; reverse primer, <named-content content-type="gene">5&#x02032;-CTAATTCCTCCTTGGCCCCACT</named-content><xref ref-type="bibr" rid="pntd.0000375-Kouriba1">&#x0005b;29&#x0005d;</xref>. PCR of the IL-13 &#x0002b;130 G/A was conducted in a 50 &#x000b5;l reaction containing 100 ng DNA, 5 &#x000b5;l of 1&#x000d7; Qiagen PCR buffer, 0.5 &#x000b5;M of each dNTP, 0.4 &#x000b5;M of each primer, 1 mM MgCl<sub>2</sub>, and 2.5 U of <italic>Taq</italic> polymerase (Qiagen). Initial denaturation was performed at 94&#x000b0;C for 5 min followed by 34 cycles of PCR with the following conditions: 94&#x000b0;C for 1 min, 60&#x000b0;C for 45 sec for annealing, 72&#x000b0;C for 45 sec, and a final 72&#x000b0;C for 3 min. The following sequences were used: forward primer, <named-content content-type="gene">5&#x02032;-TGGCGTTCTACTCACGTGCT</named-content>; reverse primer, <named-content content-type="gene">5&#x02032;-CAGCACAGGCTGAGGTCTAA</named-content><xref ref-type="bibr" rid="pntd.0000375-Heinzmann1">&#x0005b;43&#x0005d;</xref>. PCR of the IL-4 &#x02212;590 C/T was conducted in a 50 &#x000b5;l reaction containing 100 ng DNA, 5 &#x000b5;l of 1&#x000d7; Qiagen PCR buffer, 0.5 &#x000b5;M of each dNTP, 0.4 &#x000b5;M of each primer, 1 mM MgCl<sub>2</sub>, and 2.5 U of <italic>Taq</italic> polymerase (Qiagen). Initial denaturation was performed at 95&#x000b0;C for 5 min followed by 31 cycles of PCR with the following conditions: 94&#x000b0;C for 30 sec, 59&#x000b0;C for 30 sec for annealing, 72&#x000b0;C for 30 sec, and a final 72&#x000b0;C for 3 min. The following sequences were used: forward primer, <named-content content-type="gene">5&#x02032;-ACTAGGCCTCACCTGATACG</named-content>; reverse primer, <named-content content-type="gene">5&#x02032;-GTTGTAATGCAGTCCTCCTG</named-content><xref ref-type="bibr" rid="pntd.0000375-Gyan1">&#x0005b;44&#x0005d;</xref>.</p></sec><sec id="s2d"><title>Genotyping</title><p>Purified PCR products of the IL-13 &#x02212;1055 C/T and IL-4 &#x02212;590 C/T PCR reactions were sequenced using the reverse primers for each and the forward primers for IL-13 &#x0002b;130 G/A and IL-13 &#x02212;591 A/G on an ABI 3100 by the Office of Research Services at The University of Georgia. The polymorphisms IL-10 &#x02212;1082, IL-10 &#x02212;819, IL-10 &#x02212;592, and IFN-&#x003b3; &#x0002b;874A/T were genotyped using sequence-specific primers (SSP) in The Cytokine Genotyping Tray (One Lambda; Canoga Park, CA) as per the manufacturer's instructions.</p></sec><sec id="s2e"><title>Resistance</title><p>Resistance is based on the number of cars washed from the time of a successful cure until the next reinfection. For all participants, the number of cars washed between each cure and reinfection over the entire duration of the study was plotted and the patterns examined. Two dominant patterns emerged, with participants either becoming reinfected after washing approximately the same number of cars between each cure and reinfection or participants washing progressively more cars between successive cure-reinfection intervals. The majority of those in the former group (classified as &#x0201c;susceptible&#x0201d;) became reinfected after washing approximately 250&#x02013;300 cars regardless of how many times they were cured and reinfected. Those men who demonstrated a pattern of increasing numbers of cars washed before subsequent reinfections were classified as &#x0201c;developing resistance&#x0201d; during this study. All men classified as &#x0201c;developing resistance&#x0201d; eventually washed at least 450 cars before reinfection after being followed for at least 3 cure-to-reinfection intervals. Some men (classified as &#x0201c;initially resistant&#x0201d;) washed at least 450 cars after the initial cure and continued to wash a high number of cars before each reinfection. For analysis purposes, men classified as &#x0201c;developing resistance&#x0201d; and &#x0201c;initially resistant&#x0201d; were grouped into a single &#x0201c;resistant&#x0201d; category because frequencies of genotypes did not differ significantly between these two groups, and conceptually these groups indicate either the existence of established resistance or the ability to develop resistance. Resistance data are based on a mean follow-up time of 7.5 years (range 0.9&#x02013;12.2 yrs) months and a mean of 7 cure-to-reinfection intervals. Men were excluded from the analysis when the number of cars washed between each cure and reinfection could not be classified into a particular pattern (3 men) or they had insufficient follow up data (16 men) for accurate classification.</p></sec><sec id="s2f"><title>Statistical methods</title><p>Odds ratios (ORs) and corresponding 95&#x00025; confidence intervals (CIs) for the association between resistance and each genotype were calculated using univariate analyses and in a multivariate logistic regression model containing variables for all three genotypes. To test for interactions between genotypes, categorical interaction terms with 4 levels were created for each possible two-way interaction between the 3 dichotomized genotypes. The combination of alleles with the lowest frequency of resistant subjects was considered the referent category in each set of terms. Separate logistic regression models were run for each series of two-way interaction terms. Inclusion of a term for the third genotype did not appreciably change the results of any of the interaction models and was thus ultimately not included in any of the reported analyses of interactions.</p><p>Interactions were assessed on both a multiplicative and additive scale. Multiplicative interactions are indicative of the need to estimate stratum-specific effects for the combination of two genotypes, rather than a single estimate for each genotype, in order to improve the fit of the model to the data <xref ref-type="bibr" rid="pntd.0000375-Ahlbom1">&#x0005b;45&#x0005d;</xref>. Multiplicative interactions were assessed by testing the significance of an interaction term between two genotypes in the logistic regression models by the Wald test. As many researchers believe that departure from additivity is a better indicator of biologic interaction than departure from multiplicativity <xref ref-type="bibr" rid="pntd.0000375-Ahlbom1">&#x0005b;45&#x0005d;</xref>,<xref ref-type="bibr" rid="pntd.0000375-Kalilani1">&#x0005b;46&#x0005d;</xref>, we also calculated the attributable proportion (AP) of resistance due to interactions between two genotypes. A positive AP is indicative of synergy between the two genotypes, while a negative AP indicates antagonism <xref ref-type="bibr" rid="pntd.0000375-Rothman1">&#x0005b;47&#x0005d;</xref>. APs and corresponding 95&#x00025; CIs for each of the two-way interactions between genotypes were calculated based on the output from the logistic regression models using the code provided by Andersson et al <xref ref-type="bibr" rid="pntd.0000375-Andersson1">&#x0005b;48&#x0005d;</xref> based on the methodology described by Hosmer and Lemeshow <xref ref-type="bibr" rid="pntd.0000375-Hosmer1">&#x0005b;49&#x0005d;</xref>. All analyses were performed with SAS version 9.1.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Distribution of genotypes and resistance</title><p>The distribution of genotypes for each polymorphism and frequency of resistance in each genotype are given in <xref ref-type="table" rid="pntd-0000375-t001">Table 1</xref>. A higher percentage of car washers with a T allele (T/T or T/A) at IFN-&#x003b3; &#x0002b;874 are resistant (T/A 65.2&#x00025; and T/T 77.8&#x00025;) than men that are A/A homozygous (38.9&#x00025;). For subsequent analyses, men with T/A and T/T at the IFN-&#x003b3; &#x0002b;874 position were grouped as the occurrence of resistance for each was significantly higher when compared to homozygous individuals (A/A) and they did not differ from each other. Among men heterozygous (C/T) at the IL-13 &#x02212;1055 position, 76.0&#x00025; were resistant to reinfection; whereas only 41.9&#x00025; of C/C and only 42.9&#x00025; of T/T individuals were resistant to reinfection (<xref ref-type="table" rid="pntd-0000375-t001">Table 1</xref>). Both homozygous genotypes for IL-13 &#x02212;1055 were grouped for the univariate analysis as the occurrences of resistance in either of those genotypes were substantially lower than in the heterozygous group and they did not differ from each other. The frequency of homozygous C/C at IL-4 &#x02212;590 was not high enough in our cohort of men to allow analysis. However, men heterozygous (C/T) at IL-4 &#x02212;590 represent a higher percentage of resistance (70.8&#x00025;) than men that are T/T homozygous (40.9&#x00025;). No overt differences are seen in the proportions of the different genotypes of IL-10 (&#x02212;1082; &#x02212;819; &#x02212;592) promoter SNPs in relationship to resistance or susceptibility to reinfection, and as expected due to linkage disequilibrium, SNPs at IL-10 &#x02212;819 and IL-10 &#x02212;592 segregate together.</p><table-wrap id="pntd-0000375-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000375.t001</object-id><label>Table 1</label><caption><title>IFN-&#x003b3; &#x0002b;874, IL-13 &#x02212;1055, IL-13 &#x0002b;130, IL-13 &#x02212;591, IL-4 &#x02212;590, IL-10 &#x02212;1082, IL-10 &#x02212;819 and IL-10 &#x02212;592 genotype distributions and percentage of resistance.</title></caption><graphic id="pntd-0000375-t001-1" xlink:href="pntd.0000375.t001"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000375-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">Total N</td><td align="left" rowspan="1" colspan="1">N (&#x00025; susceptible)</td><td align="left" rowspan="1" colspan="1">N (&#x00025; resistant)</td></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1"><bold>IFN-&#x003b3; &#x0002b;874</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">A/A</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">22 (61.1&#x00025;)</td><td align="left" rowspan="1" colspan="1">14 (38.9&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">T/A</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">8 (34.8&#x00025;)</td><td align="left" rowspan="1" colspan="1">15 (65.2&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">T/T</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">2 (22.2&#x00025;)</td><td align="left" rowspan="1" colspan="1">7 (77.8&#x00025;)</td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>IL-13 &#x02212;1055</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">18 (58.1&#x00025;)</td><td align="left" rowspan="1" colspan="1">13 (41.9&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">6 (24&#x00025;)</td><td align="left" rowspan="1" colspan="1">19 (76&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">T/T</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">4 (57.1&#x00025;)</td><td align="left" rowspan="1" colspan="1">3 (42.9&#x00025;)</td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>IL-13 &#x0002b;130</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">A/A</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">2 (28.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">5 (71.4&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">8 (34.8&#x00025;)</td><td align="left" rowspan="1" colspan="1">15 (65.2&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">G/G</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">18 (54.5&#x00025;)</td><td align="left" rowspan="1" colspan="1">15 (45.5&#x00025;)</td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>IL-13 &#x02212;591</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">A/A</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">26 (47.3&#x00025;)</td><td align="left" rowspan="1" colspan="1">29 (52.7&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">2 (25&#x00025;)</td><td align="left" rowspan="1" colspan="1">6 (75.0&#x00025;)</td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>IL-4 &#x02212;590</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (100&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">7 (29.2&#x00025;)</td><td align="left" rowspan="1" colspan="1">17 (70.8&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">T/T</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">26 (59.1&#x00025;)</td><td align="left" rowspan="1" colspan="1">18 (40.9&#x00025;)</td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>IL-10 &#x02212;1082</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">A/A</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">21 (52.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">18 (47.4&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">12 (44.4&#x00025;)</td><td align="left" rowspan="1" colspan="1">15 (55.6&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">G/G</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1 (25&#x00025;)</td><td align="left" rowspan="1" colspan="1">3 (75.0&#x00025;)</td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>IL-10 &#x02212;819</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">5 (35.7&#x00025;)</td><td align="left" rowspan="1" colspan="1">9 (64.3&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">17 (43.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">22 (56.4&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">T/T</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">11 (68.7&#x00025;)</td><td align="left" rowspan="1" colspan="1">5 (31.3&#x00025;)</td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>IL-10 &#x02212;592</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">5 (35.7&#x00025;)</td><td align="left" rowspan="1" colspan="1">9 (64.3&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">C/A</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">17 (43.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">22 (56.4&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">A/A</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">11 (68.7&#x00025;)</td><td align="left" rowspan="1" colspan="1">5 (31.3&#x00025;)</td></tr></tbody></table></table-wrap></sec><sec id="s3b"><title>Polymorphisms in IL-13, IFN-&#x003b3;, IL-4, and IL-10 and resistance</title><p>Resistance was significantly associated with the T allele at IFN-&#x003b3; &#x0002b;874 (TT and TA) when compared to the homozygous A/A individuals (OR 3.5 &#x0005b;CI 1.3, 9.4&#x0005d;) (<xref ref-type="table" rid="pntd-0000375-t002">Table 2</xref>). Car washers heterozygous (C/T) at the IL-13 &#x02212;1055 position also showed a significant correlation with resistance to reinfection when compared to homozygous (C/C and T/T) car washers (OR 4.4 &#x0005b;CI 1.4, 13.4&#x0005d;) (<xref ref-type="table" rid="pntd-0000375-t002">Table 2</xref>), and heterozygousity (C/T) at the IL-4 &#x02212;590 position correlated significantly with resistance when compared to homozygous (T/T) car washers (OR 3.5 &#x0005b;CI 1.2, 10.2&#x0005d;) (<xref ref-type="table" rid="pntd-0000375-t002">Table 2</xref>). These associations remained significant when all three genotypes were included in a multivariate analysis, indicating an independent association between resistance and each of the 3 genotypes (<xref ref-type="table" rid="pntd-0000375-t002">Table 2</xref>). For IL-13 &#x02212;591, there was no significant difference in resistance between the A/A and A/G genotypes (<xref ref-type="table" rid="pntd-0000375-t001">Table 1</xref>, p&#x0200a;&#x0003d;&#x0200a;0.2399). Having an A allele at the IL-13 &#x0002b;130 position was associated with a modest increase in resistance relative to the homozygous G/G genotype (OR&#x0200a;&#x0003d;&#x0200a;2.4 &#x0005b;0.9, 6.7&#x0005d;). However, when IL-13 &#x0002b;130 and IL-13 &#x02212;1055 were evaluated simultaneously in a logistic regression model, the association between resistance and IL-13 &#x0002b;130 disappeared (OR&#x0200a;&#x0003d;&#x0200a;1.4 &#x0005b;0.4, 4.5&#x0005d;), while IL-13 &#x02212;1055 remained significantly associated with resistance. This suggests that the observed relationship between resistance and IL-13 &#x0002b;130 was spurious and likely due to the close association between IL-13 &#x0002b;130 and IL-13 &#x02212;1055. Therefore, we only included the IL-13 &#x02212;1055 polymorphism in further analyses.</p><table-wrap id="pntd-0000375-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000375.t002</object-id><label>Table 2</label><caption><title>Odds ratios for the associations between individual genotypes and resistance to reinfection by univariate and multivariate analysis.</title></caption><graphic id="pntd-0000375-t002-2" xlink:href="pntd.0000375.t002"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000375-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype</td><td colspan="2" align="left" rowspan="1">Univariate</td><td colspan="2" align="left" rowspan="1">Multivariate<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IL-13 &#x02212;1055 (C/T vs CC/TT)</td><td align="left" rowspan="1" colspan="1">4.4 (1.4, 13.4)</td><td align="left" rowspan="1" colspan="1">0.0086</td><td align="left" rowspan="1" colspan="1">6.3 (1.5, 26.0)</td><td align="left" rowspan="1" colspan="1">0.0109</td></tr><tr><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; &#x0002b;874 (TT/TA vs A/A)</td><td align="left" rowspan="1" colspan="1">3.5 (1.2, 9.4)</td><td align="left" rowspan="1" colspan="1">0.0145</td><td align="left" rowspan="1" colspan="1">9.0 (2.0, 38.3)</td><td align="left" rowspan="1" colspan="1">0.0030</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-4 &#x02212;590 (C/T vs T/T)</td><td align="left" rowspan="1" colspan="1">3.5 (1.2, 10.2)</td><td align="left" rowspan="1" colspan="1">0.0192</td><td align="left" rowspan="1" colspan="1">4.3 (1.1, 17.4)</td><td align="left" rowspan="1" colspan="1">0.0419</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>adjusted for the other 2 genotypes.</p></fn></table-wrap-foot></table-wrap><p>We found a relationship of borderline significance with IL-10 &#x02212;819 or &#x02212;592 (any C versus homozygous G/G or A/A): (OR&#x0200a;&#x0003d;&#x0200a;3.1 &#x0005b;0.9, 10.2&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.0577) and resistance to reinfection. These two (&#x02212;819 and &#x02212;592) polymorphisms are in tight linkage disequilibrium; hence the results are interchangeable between the two. The OR remained virtually unchanged in a model controlling for the other three significant genotypes, indicating that this possible low-grade association between resistance and the IL-10 polymorphism was not confounded by its association with another genotype. There were no significant additive or multiplicative interactions between IL-10 &#x02212;819 or &#x02212;592 and any of the IL-4, IL-13 or IFN-&#x003b3; polymorphisms. No significant associations were found with IL-10 &#x02212;1082 with resistance or susceptibility (data not shown).</p></sec><sec id="s3c"><title>Associations between genotype and resistance within categories of genotype interactions</title><p>Combination of the IL-13 &#x02212;1055 and IFN-&#x003b3; &#x0002b;874 genotypes that were independently associated with resistance did not increase the odds of being resistant over having either one of these genotypes alone. However, although all combinations of IL-13 and IFN-&#x003b3; genotypes had comparable odds of resistance when compared to the reference group (<xref ref-type="table" rid="pntd-0000375-t003">Table 3</xref>), effect modification was seen between the IL-13 and IFN-&#x003b3; genotypes. Among men with a homozygous IL-13 genotype, having a T allele at the IFN-&#x003b3; &#x0002b;874 position increased the odds of resistance relative to those with the A/A genotype (OR&#x0200a;&#x0003d;&#x0200a;17.5 &#x0005b;CI 3.0, 101.5&#x0005d;) (<xref ref-type="table" rid="pntd-0000375-t003">Table 3</xref>). There was no association between IFN-&#x003b3; genotype and resistance among men with the heterozygous C/T IL-13 genotype. Likewise, among men with homozygous A/A IFN-&#x003b3; genotype, the heterozygous IL-13 genotype was associated with resistance relative to the homozygous C/C or T/T genotypes (OR&#x0200a;&#x0003d;&#x0200a;22.5 &#x0005b;CI 3.5, 144.4&#x0005d;) (<xref ref-type="table" rid="pntd-0000375-t003">Table 3</xref>), while no association between IL-13 and resistance was seen among men with a T allele in the IFN-&#x003b3; gene.</p><table-wrap id="pntd-0000375-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0000375.t003</object-id><label>Table 3</label><caption><title>Odds ratios for the associations between genotype and resistance within categories of genotype interaction.</title></caption><graphic id="pntd-0000375-t003-3" xlink:href="pntd.0000375.t003"/><table frame="hsides" rules="groups" alternate-form-of="pntd-0000375-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Interaction categories</td><td align="left" rowspan="1" colspan="1">Odds Ratio (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">Measures of interaction</td><td align="left" rowspan="1" colspan="1">n (&#x00025;) resistant</td></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1"><bold>IL-13 and IFN-&#x003b3;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">IL-13 CT, IFN-&#x003b3; TA/TT</td><td align="left" rowspan="1" colspan="1">26.3 (3.0, 226.6)</td><td align="left" rowspan="1" colspan="1">AP<xref ref-type="table-fn" rid="nt102">&#x0002b;</xref>&#x0200a;&#x0003d;&#x0200a;&#x02212;0.49 (&#x02212;3.09, 2.12)</td><td align="left" rowspan="1" colspan="1">7 (77.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-13 CT, IFN-&#x003b3; AA</td><td align="left" rowspan="1" colspan="1">22.5 (3.5, 144.4)</td><td align="left" rowspan="1" colspan="1">Wald p-value<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;0.047</td><td align="left" rowspan="1" colspan="1">12 (75.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-13 CC/TT IFN-&#x003b3; TA/TT</td><td align="left" rowspan="1" colspan="1">17.5 (3.0, 101.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">14 (70.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-13 CC/TT, IFN-&#x003b3; AA</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2 (11.8)</td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>IL-13 and IL-4</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">IL-13 CT, IL-4 CT</td><td align="left" rowspan="1" colspan="1">20.1 (2.3, 176.0)</td><td align="left" rowspan="1" colspan="1">AP<xref ref-type="table-fn" rid="nt102">&#x0002b;</xref>&#x0200a;&#x0003d;&#x0200a;0.90 (0.64, 1.15)</td><td align="left" rowspan="1" colspan="1">13 (92.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-13 CT, IL-4 TT</td><td align="left" rowspan="1" colspan="1">1.9 (0.5, 7.6)</td><td align="left" rowspan="1" colspan="1">Wald p-value<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;0.105</td><td align="left" rowspan="1" colspan="1">6 (54.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-13 CC, IL-4 CT</td><td align="left" rowspan="1" colspan="1">1.3 (0.3, 5.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4 (44.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-13 CC/TT, IL-4 TT</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">11 (39.3)</td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>IL-4 and IFN-&#x003b3;</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">IL-4 CT, IFN-&#x003b3; TA/TT</td><td align="left" rowspan="1" colspan="1">14.9 (2.2, 100.7)</td><td align="left" rowspan="1" colspan="1">AP<xref ref-type="table-fn" rid="nt102">&#x0002b;</xref>&#x0200a;&#x0003d;&#x0200a;0 (&#x02212;1.75, 1.75)</td><td align="left" rowspan="1" colspan="1">7 (77.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-4 TT, IFN-&#x003b3; TA/TT</td><td align="left" rowspan="1" colspan="1">7.4 (1.9, 30.0)</td><td align="left" rowspan="1" colspan="1">Wald p-value<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref>&#x0200a;&#x0003d;&#x0200a;0.240</td><td align="left" rowspan="1" colspan="1">14 (63.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-4 CT, IFN-&#x003b3; AA</td><td align="left" rowspan="1" colspan="1">8.5 (1.8, 39.2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10 (66.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-4 TT, IFN-&#x003b3; AA</td><td align="left" rowspan="1" colspan="1">Ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4 (19.1)</td></tr></tbody></table><table-wrap-foot><fn id="nt102"><label>&#x0002b;</label><p>AP&#x0200a;&#x0003d;&#x0200a;attributable proportion.</p></fn><fn id="nt103"><label>&#x0002a;</label><p>Wald test for interaction term in logistic regression model.</p></fn></table-wrap-foot></table-wrap><p>Men with a combination of the heterozygous C/T alleles for IL-13 &#x02212;1055 and IL-4 &#x02212;590 genes had more than a 20-fold increased odds of resistance relative to those with homozygous alleles at both genes (OR&#x0200a;&#x0003d;&#x0200a;20.1 &#x0005b;CI 2.3, 176.0&#x0005d;) (<xref ref-type="table" rid="pntd-0000375-t003">Table 3</xref>). Men who were heterozygous for only one of the IL-13 or IL-4 genes were not more likely to be resistant compared to men with both homozygous alleles (<xref ref-type="table" rid="pntd-0000375-t003">Table 3</xref>). A significant additive interaction between IL-13 and IL-4 genotypes was detected, with 90&#x00025; of the resistance among those with heterozygous alleles at both genes attributable to the interaction between the two genes (AP&#x0200a;&#x0003d;&#x0200a;0.90 &#x0005b;0.64, 1.15&#x0005d;). In contrast, no significant additive or multiplicative interactions were detected between IL-4 &#x02212;590 and IFN-&#x003b3; &#x0002b;874 (<xref ref-type="table" rid="pntd-0000375-t003">Table 3</xref>).</p></sec></sec><sec id="s4"><title>Discussion</title><p>The car washers in this study are part of a longitudinal study that dates back 12 years <xref ref-type="bibr" rid="pntd.0000375-Karanja1">&#x0005b;40&#x0005d;</xref>. Their exposure (water contact) to infection with <italic>S. mansoni</italic> is documented by the number of cars washed for payment purposes, providing us with a unique, reliable means to quantify an individual's exposure in an active transmission site over time. This longitudinal field setting allows us to account for water contact as a variable and pose some interesting immunologic and genetic questions with regard to what influences may play a role in determining resistance to reinfection after treatment.</p><p>We found significant correlates between resistance to reinfection with <italic>S. mansoni</italic> and the heterozygous (C/T) IL-13 &#x02212;1055 genotype, any T allele in the IFN-&#x003b3; &#x0002b;874 genotype, and the heterozygous (C/T) in the IL-4 &#x02212;590 genotype by univariate analysis. Furthermore, these associations remained significant when all three genotypes were included in a multivariate analysis, indicating independent associations between resistance and each of the 3 genotypes. However, our data suggest that having a combination of the IL-13 C/T and an IFN-&#x003b3; T allele at &#x0002b;874 does not provide increased odds of being resistant over having just one of these genotypes. Instead, both IL-13 C/T and any IFN-&#x003b3; T allele demonstrated very high odds of being resistant when compared to the reference group. Our data did, however, show a significant synergistic effect between the IL-13 &#x02212;1055 C/T and IL-4 &#x02212;590 C/T genotypes. Thus, the proportion of resistant men seen with a combination of these two cytokine genotypes was much greater than that seen with the sum of the separate effects of IL-13 &#x02212;1055 C/T and IL-4 &#x02212;590 C/T on resistance. We interpret these data to indicate that individuals heterozygous at the IL-13 &#x02212;1055 and IL-4 &#x02212;590 position are more likely to require fewer reinfections and treatments to become resistant to reinfection than individuals who are homozygous at either position.</p><p>Due to our small sample size, our interaction analysis resulted in wide confidence intervals and we were unable to evaluate 3-way interactions between groups. Also, because car washing is an exclusively male profession at this study site, the associations in this study apply to men and cannot necessarily be generalized to women. However, these analyses provide interesting findings in a situation that provides exceptional exposure data that are not generally available in studies of resistance to reinfection. Clearly our findings need to be investigated further in larger cohorts. However, the current data provide initial insights into the potential genetic foundation of propensities of people to develop resistance to reinfection by schistosomes, and they offer a basis for further molecular studies of how these polymorphisms might work at the transcriptional and gene product level.</p></sec></body><back><ref-list><title>References</title><ref id="pntd.0000375-Butterworth1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Butterworth</surname><given-names>AE</given-names></name><name><surname>Capron</surname><given-names>M</given-names></name><name><surname>Cordingley</surname><given-names>JS</given-names></name><name><surname>Dalton</surname><given-names>PR</given-names></name><name><surname>Dunne</surname><given-names>DW</given-names></name><etal/></person-group><year>1985</year><article-title>Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses.</article-title><source>Trans R Soc Trop Med Hyg</source><volume>79</volume><fpage>393</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">4035741</pub-id></citation></ref><ref id="pntd.0000375-Dunne1"><label>2</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Dunne</surname><given-names>D</given-names></name><name><surname>Mountford</surname><given-names>A</given-names></name></person-group><year>2001</year><article-title>Resistance to infection in humans and animal models.</article-title><person-group person-group-type="editor"><name><surname>Mahmoud</surname><given-names>A</given-names></name></person-group><source>Schistosomiasis</source><publisher-loc>London, UK</publisher-loc><publisher-name>Imperial College Press</publisher-name><fpage>133</fpage><lpage>212</lpage></citation></ref><ref id="pntd.0000375-Li1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YS</given-names></name><name><surname>Sleigh</surname><given-names>AC</given-names></name><name><surname>Ross</surname><given-names>AG</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Williams</surname><given-names>GM</given-names></name><etal/></person-group><year>1999</year><article-title>A 2-year prospective study in China provides epidemiological evidence for resistance in humans to re-infection with Schistosoma japonicum.</article-title><source>Ann Trop Med Parasitol</source><volume>93</volume><fpage>629</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">10707108</pub-id></citation></ref><ref id="pntd.0000375-Wilkins1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilkins</surname><given-names>HA</given-names></name><name><surname>Blumenthal</surname><given-names>UJ</given-names></name><name><surname>Hagan</surname><given-names>P</given-names></name><name><surname>Hayes</surname><given-names>RJ</given-names></name><name><surname>Tulloch</surname><given-names>S</given-names></name></person-group><year>1987</year><article-title>Resistance to reinfection after treatment of urinary schistosomiasis.</article-title><source>Trans R Soc Trop Med Hyg</source><volume>81</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">3127957</pub-id></citation></ref><ref id="pntd.0000375-Caldas1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caldas</surname><given-names>IR</given-names></name><name><surname>Correa-Oliveira</surname><given-names>R</given-names></name><name><surname>Colosimo</surname><given-names>E</given-names></name><name><surname>Carvalho</surname><given-names>OS</given-names></name><name><surname>Massara</surname><given-names>CL</given-names></name><etal/></person-group><year>2000</year><article-title>Susceptibility and resistance to <italic>Schistosoma mansoni</italic> reinfection: parallel cellular and isotypic immunologic assessment.</article-title><source>Am J Trop Med Hyg</source><volume>62</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">10761724</pub-id></citation></ref><ref id="pntd.0000375-Demeure1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demeure</surname><given-names>CE</given-names></name><name><surname>Rihet</surname><given-names>P</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Ouattara</surname><given-names>M</given-names></name><name><surname>Bourgois</surname><given-names>A</given-names></name><etal/></person-group><year>1993</year><article-title>Resistance to <italic>Schistosoma mansoni</italic> in humans: influence of the IgE/IgG4 balance and IgG2 in immunity to reinfection after chemotherapy.</article-title><source>J Infect Dis</source><volume>168</volume><fpage>1000</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">7690821</pub-id></citation></ref><ref id="pntd.0000375-Gomes1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>YM</given-names></name><name><surname>Gomes</surname><given-names>FC</given-names></name><name><surname>Furtado</surname><given-names>VC</given-names></name><name><surname>Teixeira</surname><given-names>KM</given-names></name><name><surname>Souza</surname><given-names>WV</given-names></name><etal/></person-group><year>1998</year><article-title>IgE and IgG4 antibodies in subjects reinfected with <italic>Schistosoma mansoni</italic> in an endemic area of northeast Brazil.</article-title><source>Mem Inst Oswaldo Cruz</source><volume>93</volume><issue>Suppl 1</issue><fpage>183</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">9921346</pub-id></citation></ref><ref id="pntd.0000375-Gounni1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gounni</surname><given-names>AS</given-names></name><name><surname>Lamkhioued</surname><given-names>B</given-names></name><name><surname>Ochiai</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Delaporte</surname><given-names>E</given-names></name><etal/></person-group><year>1994</year><article-title>High-affinity IgE receptor on eosinophils is involved in defence against parasites.</article-title><source>Nature</source><volume>367</volume><fpage>183</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">8114916</pub-id></citation></ref><ref id="pntd.0000375-Grogan1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grogan</surname><given-names>JL</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>van Dam</surname><given-names>GJ</given-names></name><name><surname>Deelder</surname><given-names>AM</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>M</given-names></name></person-group><year>1997</year><article-title>Anti-schistosome IgG4 and IgE at 2 years after chemotherapy: infected versus uninfected individuals.</article-title><source>J Infect Dis</source><volume>176</volume><fpage>1344</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">9359737</pub-id></citation></ref><ref id="pntd.0000375-Grogan2"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grogan</surname><given-names>JL</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>van Dam</surname><given-names>GJ</given-names></name><name><surname>Metzger</surname><given-names>W</given-names></name><name><surname>Mordmuller</surname><given-names>B</given-names></name><etal/></person-group><year>1996</year><article-title>Antischistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults.</article-title><source>J Infect Dis</source><volume>173</volume><fpage>1242</fpage><lpage>1247</lpage><pub-id pub-id-type="pmid">8627078</pub-id></citation></ref><ref id="pntd.0000375-Hagan1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hagan</surname><given-names>P</given-names></name><name><surname>Blumenthal</surname><given-names>UJ</given-names></name><name><surname>Dunn</surname><given-names>D</given-names></name><name><surname>Simpson</surname><given-names>AJ</given-names></name><name><surname>Wilkins</surname><given-names>HA</given-names></name></person-group><year>1991</year><article-title>Human IgE, IgG4 and resistance to reinfection with <italic>Schistosoma haematobium</italic>.</article-title><source>Nature</source><volume>349</volume><fpage>243</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">1898985</pub-id></citation></ref><ref id="pntd.0000375-Li2"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>King</surname><given-names>CL</given-names></name><name><surname>Ogundipe</surname><given-names>JO</given-names></name><name><surname>Licate</surname><given-names>LS</given-names></name><name><surname>Blanton</surname><given-names>RE</given-names></name></person-group><year>1995</year><article-title>Preferential recognition by human IgE and IgG4 of a species-specific <italic>Schistosoma haematobium</italic> serine protease inhibitor.</article-title><source>J Infect Dis</source><volume>171</volume><fpage>416</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">7844379</pub-id></citation></ref><ref id="pntd.0000375-Rihet1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rihet</surname><given-names>P</given-names></name><name><surname>Demeure</surname><given-names>CE</given-names></name><name><surname>Bourgois</surname><given-names>A</given-names></name><name><surname>Prata</surname><given-names>A</given-names></name><name><surname>Dessein</surname><given-names>AJ</given-names></name></person-group><year>1991</year><article-title>Evidence for an association between human resistance to <italic>Schistosoma mansoni</italic> and high anti-larval IgE levels.</article-title><source>Eur J Immunol</source><volume>21</volume><fpage>2679</fpage><lpage>2686</lpage><pub-id pub-id-type="pmid">1936116</pub-id></citation></ref><ref id="pntd.0000375-Satti1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Satti</surname><given-names>MZ</given-names></name><name><surname>Cahen</surname><given-names>P</given-names></name><name><surname>Skov</surname><given-names>PS</given-names></name><name><surname>Joseph</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>FM</given-names></name><etal/></person-group><year>2004</year><article-title>Changes in IgE- and Antigen-dependent histamine-release in peripheral blood of <italic>Schistosoma mansoni</italic>-infected Ugandan fishermen after treatment with praziquantel.</article-title><source>BMC Immunol</source><volume>5</volume><fpage>6</fpage><pub-id pub-id-type="pmid">15102330</pub-id></citation></ref><ref id="pntd.0000375-vanDerKleij1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Der Kleij</surname><given-names>D</given-names></name><name><surname>Tielens</surname><given-names>AG</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>M</given-names></name></person-group><year>1999</year><article-title>Recognition of schistosome glycolipids by immunoglobulin E: possible role in immunity.</article-title><source>Infect Immun</source><volume>67</volume><fpage>5946</fpage><lpage>5950</lpage><pub-id pub-id-type="pmid">10531252</pub-id></citation></ref><ref id="pntd.0000375-Webster1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>M</given-names></name><name><surname>Fallon</surname><given-names>PG</given-names></name><name><surname>Fulford</surname><given-names>AJ</given-names></name><name><surname>Butterworth</surname><given-names>AE</given-names></name><name><surname>Ouma</surname><given-names>JH</given-names></name><etal/></person-group><year>1997</year><article-title>IgG4 and IgE responses to <italic>Schistosoma mansoni</italic> adult worms after treatment.</article-title><source>J Infect Dis</source><volume>175</volume><fpage>493</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">9203682</pub-id></citation></ref><ref id="pntd.0000375-Webster2"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>M</given-names></name><name><surname>Fulford</surname><given-names>AJ</given-names></name><name><surname>Braun</surname><given-names>G</given-names></name><name><surname>Ouma</surname><given-names>JH</given-names></name><name><surname>Kariuki</surname><given-names>HC</given-names></name><etal/></person-group><year>1996</year><article-title>Human immunoglobulin E responses to a recombinant 22.6-kilodalton antigen from <italic>Schistosoma mansoni</italic> adult worms are associated with low intensities of reinfection after treatment.</article-title><source>Infect Immun</source><volume>64</volume><fpage>4042</fpage><lpage>4046</lpage><pub-id pub-id-type="pmid">8926066</pub-id></citation></ref><ref id="pntd.0000375-Zhang1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><etal/></person-group><year>1997</year><article-title>Association between IgE antibody against soluble egg antigen and resistance to reinfection with <italic>Schistosoma japonicum</italic>.</article-title><source>Trans R Soc Trop Med Hyg</source><volume>91</volume><fpage>606</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">9463682</pub-id></citation></ref><ref id="pntd.0000375-Brito1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brito</surname><given-names>CF</given-names></name><name><surname>Caldas</surname><given-names>IR</given-names></name><name><surname>Coura Filho</surname><given-names>P</given-names></name><name><surname>Correa-Oliveira</surname><given-names>R</given-names></name><name><surname>Oliveira</surname><given-names>SC</given-names></name></person-group><year>2000</year><article-title>CD4&#x0002b; T cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-gamma and tumour necrosis factor-alpha in response to the recombinant 14KDA Schistosoma mansoni fatty acid-binding protein.</article-title><source>Scand J Immunol</source><volume>51</volume><fpage>595</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">10849370</pub-id></citation></ref><ref id="pntd.0000375-ElRidi1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El Ridi</surname><given-names>R</given-names></name><name><surname>Farouk</surname><given-names>F</given-names></name><name><surname>Sherif</surname><given-names>M</given-names></name><name><surname>Al-Sherbiny</surname><given-names>M</given-names></name><name><surname>Osman</surname><given-names>A</given-names></name><etal/></person-group><year>1998</year><article-title>T and B cell reactivity to a 42-kDa protein is associated with human resistance to both schistosomiasis mansoni and haematobium.</article-title><source>J Infect Dis</source><volume>177</volume><fpage>1364</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">9593026</pub-id></citation></ref><ref id="pntd.0000375-RibeirodeJesus1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro de Jesus</surname><given-names>A</given-names></name><name><surname>Araujo</surname><given-names>I</given-names></name><name><surname>Bacellar</surname><given-names>O</given-names></name><name><surname>Magalhaes</surname><given-names>A</given-names></name><name><surname>Pearce</surname><given-names>E</given-names></name><etal/></person-group><year>2000</year><article-title>Human immune responses to <italic>Schistosoma mansoni</italic> vaccine candidate antigens.</article-title><source>Infect Immun</source><volume>68</volume><fpage>2797</fpage><lpage>2803</lpage><pub-id pub-id-type="pmid">10768975</pub-id></citation></ref><ref id="pntd.0000375-Viana1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viana</surname><given-names>IR</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><name><surname>Carvalho</surname><given-names>OS</given-names></name><name><surname>Massara</surname><given-names>CL</given-names></name><name><surname>Eloi-Santos</surname><given-names>SM</given-names></name><etal/></person-group><year>1994</year><article-title>Interferon-gamma production by peripheral blood mononuclear cells from residents of an area endemic for <italic>Schistosoma mansoni</italic>.</article-title><source>Trans R Soc Trop Med Hyg</source><volume>88</volume><fpage>466</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">7570847</pub-id></citation></ref><ref id="pntd.0000375-Dessein1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dessein</surname><given-names>AJ</given-names></name><name><surname>Chevillard</surname><given-names>C</given-names></name><name><surname>Marquet</surname><given-names>S</given-names></name><name><surname>Henri</surname><given-names>S</given-names></name><name><surname>Hillaire</surname><given-names>D</given-names></name><etal/></person-group><year>2001</year><article-title>Genetics of parasitic infections.</article-title><source>Drug Metab Dispos</source><volume>29</volume><fpage>484</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">11259337</pub-id></citation></ref><ref id="pntd.0000375-Marquet1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marquet</surname><given-names>S</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Hillaire</surname><given-names>D</given-names></name><name><surname>Dessein</surname><given-names>A</given-names></name></person-group><year>1999</year><article-title>Full results of the genome-wide scan which localises a locus controlling the intensity of infection by <italic>Schistosoma mansoni</italic> on chromosome 5q31&#x02013;q33.</article-title><source>Eur J Hum Genet</source><volume>7</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">10094195</pub-id></citation></ref><ref id="pntd.0000375-Marquet2"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marquet</surname><given-names>S</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Hillaire</surname><given-names>D</given-names></name><name><surname>Dessein</surname><given-names>H</given-names></name><name><surname>Kalil</surname><given-names>J</given-names></name><etal/></person-group><year>1996</year><article-title>Genetic localization of a locus controlling the intensity of infection by <italic>Schistosoma mansoni</italic> on chromosome 5q31&#x02013;q33.</article-title><source>Nat Genet</source><volume>14</volume><fpage>181</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">8841190</pub-id></citation></ref><ref id="pntd.0000375-Wen1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>HJ</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Lee</surname><given-names>YL</given-names></name><name><surname>Guo</surname><given-names>YL</given-names></name></person-group><year>2006</year><article-title>Association between cord blood IgE and genetic polymorphisms of interleukin-4, the beta-subunit of the high-affinity receptor for IgE, lymphotoxin-alpha, and tumor necrosis factor-alpha.</article-title><source>Pediatr Allergy Immunol</source><volume>17</volume><fpage>489</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">17014622</pub-id></citation></ref><ref id="pntd.0000375-Verra1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verra</surname><given-names>F</given-names></name><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Calissano</surname><given-names>C</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Perlmann</surname><given-names>P</given-names></name><etal/></person-group><year>2004</year><article-title>IL4-589 C/T polymorphism and IgE levels in severe malaria.</article-title><source>Acta Trop</source><volume>90</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">15177147</pub-id></citation></ref><ref id="pntd.0000375-Bacharier1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bacharier</surname><given-names>LB</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name></person-group><year>2000</year><article-title>Molecular mechanisms of IgE regulation.</article-title><source>J Allergy Clin Immunol</source><volume>105</volume><fpage>S547</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">10669540</pub-id></citation></ref><ref id="pntd.0000375-Kouriba1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouriba</surname><given-names>B</given-names></name><name><surname>Chevillard</surname><given-names>C</given-names></name><name><surname>Bream</surname><given-names>JH</given-names></name><name><surname>Argiro</surname><given-names>L</given-names></name><name><surname>Dessein</surname><given-names>H</given-names></name><etal/></person-group><year>2005</year><article-title>Analysis of the 5q31&#x02013;q33 locus shows an association between IL13-1055 C/T IL-13-591A/G polymorphisms and <italic>Schistosoma haematobium</italic> infections.</article-title><source>J Immunol</source><volume>174</volume><fpage>6274</fpage><lpage>6281</lpage><pub-id pub-id-type="pmid">15879126</pub-id></citation></ref><ref id="pntd.0000375-vanderPouwKraan1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Pouw Kraan</surname><given-names>TC</given-names></name><name><surname>van Veen</surname><given-names>A</given-names></name><name><surname>Boeije</surname><given-names>LC</given-names></name><name><surname>van Tuyl</surname><given-names>SA</given-names></name><name><surname>de Groot</surname><given-names>ER</given-names></name><etal/></person-group><year>1999</year><article-title>An IL-13 promoter polymorphism associated with increased risk of allergic asthma.</article-title><source>Genes Immun</source><volume>1</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">11197307</pub-id></citation></ref><ref id="pntd.0000375-Cameron1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>L</given-names></name><name><surname>Webster</surname><given-names>RB</given-names></name><name><surname>Strempel</surname><given-names>JM</given-names></name><name><surname>Kiesler</surname><given-names>P</given-names></name><name><surname>Kabesch</surname><given-names>M</given-names></name><etal/></person-group><year>2006</year><article-title>Th2 cell-selective enhancement of human IL13 transcription by IL13-1112C&#x0003e;T, a polymorphism associated with allergic inflammation.</article-title><source>J Immunol</source><volume>177</volume><fpage>8633</fpage><lpage>8642</lpage><pub-id pub-id-type="pmid">17142763</pub-id></citation></ref><ref id="pntd.0000375-Vladich1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vladich</surname><given-names>FD</given-names></name><name><surname>Brazille</surname><given-names>SM</given-names></name><name><surname>Stern</surname><given-names>D</given-names></name><name><surname>Peck</surname><given-names>ML</given-names></name><name><surname>Ghittoni</surname><given-names>R</given-names></name><etal/></person-group><year>2005</year><article-title>IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation.</article-title><source>J Clin Invest</source><volume>115</volume><fpage>747</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">15711639</pub-id></citation></ref><ref id="pntd.0000375-Graves1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graves</surname><given-names>PE</given-names></name><name><surname>Kabesch</surname><given-names>M</given-names></name><name><surname>Halonen</surname><given-names>M</given-names></name><name><surname>Holberg</surname><given-names>CJ</given-names></name><name><surname>Baldini</surname><given-names>M</given-names></name><etal/></person-group><year>2000</year><article-title>A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children.</article-title><source>J Allergy Clin Immunol</source><volume>105</volume><fpage>506</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">10719301</pub-id></citation></ref><ref id="pntd.0000375-He1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>JQ</given-names></name><name><surname>Chan-Yeung</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>AB</given-names></name><name><surname>Dimich-Ward</surname><given-names>H</given-names></name><name><surname>Ferguson</surname><given-names>AC</given-names></name><etal/></person-group><year>2003</year><article-title>Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children.</article-title><source>Genes Immun</source><volume>4</volume><fpage>385</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">12847555</pub-id></citation></ref><ref id="pntd.0000375-Pravica1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pravica</surname><given-names>V</given-names></name><name><surname>Perrey</surname><given-names>C</given-names></name><name><surname>Stevens</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name></person-group><year>2000</year><article-title>A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production.</article-title><source>Hum Immunol</source><volume>61</volume><fpage>863</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">11053629</pub-id></citation></ref><ref id="pntd.0000375-Akdis1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akdis</surname><given-names>CA</given-names></name><name><surname>Blesken</surname><given-names>T</given-names></name><name><surname>Akdis</surname><given-names>M</given-names></name><name><surname>Alkan</surname><given-names>SS</given-names></name><name><surname>Wuthrich</surname><given-names>B</given-names></name><etal/></person-group><year>1997</year><article-title>Induction and differential regulation of bee venom phospholipase A2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells.</article-title><source>J Allergy Clin Immunol</source><volume>99</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">9058690</pub-id></citation></ref><ref id="pntd.0000375-EdwardsSmith1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards-Smith</surname><given-names>CJ</given-names></name><name><surname>Jonsson</surname><given-names>JR</given-names></name><name><surname>Purdie</surname><given-names>DM</given-names></name><name><surname>Bansal</surname><given-names>A</given-names></name><name><surname>Shorthouse</surname><given-names>C</given-names></name><etal/></person-group><year>1999</year><article-title>Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa.</article-title><source>Hepatology</source><volume>30</volume><fpage>526</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">10421663</pub-id></citation></ref><ref id="pntd.0000375-Karjalainen1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karjalainen</surname><given-names>J</given-names></name><name><surname>Hulkkonen</surname><given-names>J</given-names></name><name><surname>Nieminen</surname><given-names>MM</given-names></name><name><surname>Huhtala</surname><given-names>H</given-names></name><name><surname>Aromaa</surname><given-names>A</given-names></name><etal/></person-group><year>2003</year><article-title>Interleukin-10 gene promoter region polymorphism is associated with eosinophil count and circulating immunoglobulin E in adult asthma.</article-title><source>Clin Exp Allergy</source><volume>33</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">12534553</pub-id></citation></ref><ref id="pntd.0000375-Turner1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>DM</given-names></name><name><surname>Williams</surname><given-names>DM</given-names></name><name><surname>Sankaran</surname><given-names>D</given-names></name><name><surname>Lazarus</surname><given-names>M</given-names></name><name><surname>Sinnott</surname><given-names>PJ</given-names></name><etal/></person-group><year>1997</year><article-title>An investigation of polymorphism in the interleukin-10 gene promoter.</article-title><source>Eur J Immunogenet</source><volume>24</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9043871</pub-id></citation></ref><ref id="pntd.0000375-Karanja1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karanja</surname><given-names>DM</given-names></name><name><surname>Hightower</surname><given-names>AW</given-names></name><name><surname>Colley</surname><given-names>DG</given-names></name><name><surname>Mwinzi</surname><given-names>PN</given-names></name><name><surname>Galil</surname><given-names>K</given-names></name><etal/></person-group><year>2002</year><article-title>Resistance to reinfection with <italic>Schistosoma mansoni</italic> in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study.</article-title><source>Lancet</source><volume>360</volume><fpage>592</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">12241930</pub-id></citation></ref><ref id="pntd.0000375-Mwinzi1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mwinzi</surname><given-names>PN</given-names></name><name><surname>Karanja</surname><given-names>DM</given-names></name><name><surname>Colley</surname><given-names>DG</given-names></name><name><surname>Orago</surname><given-names>AS</given-names></name><name><surname>Secor</surname><given-names>WE</given-names></name></person-group><year>2001</year><article-title>Cellular immune responses of schistosomiasis patients are altered by human immunodeficiency virus type 1 coinfection.</article-title><source>J Infect Dis</source><volume>184</volume><fpage>488</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">11471107</pub-id></citation></ref><ref id="pntd.0000375-Howard1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>TD</given-names></name><name><surname>Koppelman</surname><given-names>GH</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>SL</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><etal/></person-group><year>2002</year><article-title>Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma.</article-title><source>Am J Hum Genet</source><volume>70</volume><fpage>230</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">11709756</pub-id></citation></ref><ref id="pntd.0000375-Heinzmann1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heinzmann</surname><given-names>A</given-names></name><name><surname>Mao</surname><given-names>XQ</given-names></name><name><surname>Akaiwa</surname><given-names>M</given-names></name><name><surname>Kreomer</surname><given-names>RT</given-names></name><name><surname>Gao</surname><given-names>PS</given-names></name><etal/></person-group><year>2000</year><article-title>Genetic variants of IL-13 signalling and human asthma and atopy.</article-title><source>Hum Mol Genet</source><volume>9</volume><fpage>549</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">10699178</pub-id></citation></ref><ref id="pntd.0000375-Gyan1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gyan</surname><given-names>BA</given-names></name><name><surname>Goka</surname><given-names>B</given-names></name><name><surname>Cvetkovic</surname><given-names>JT</given-names></name><name><surname>Kurtzhals</surname><given-names>JL</given-names></name><name><surname>Adabayeri</surname><given-names>V</given-names></name><etal/></person-group><year>2004</year><article-title>Allelic polymorphisms in the repeat and promoter regions of the interleukin-4 gene and malaria severity in Ghanaian children.</article-title><source>Clin Exp Immunol</source><volume>138</volume><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">15373917</pub-id></citation></ref><ref id="pntd.0000375-Ahlbom1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahlbom</surname><given-names>A</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name></person-group><year>2005</year><article-title>Interaction: A word with two meanings creates confusion.</article-title><source>Eur J Epidemiol</source><volume>20</volume><fpage>563</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">16119427</pub-id></citation></ref><ref id="pntd.0000375-Kalilani1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalilani</surname><given-names>L</given-names></name><name><surname>Atashili</surname><given-names>J</given-names></name></person-group><year>2006</year><article-title>Measuring additive interaction using odds ratios.</article-title><source>Epidemiol Perspect Innov</source><volume>3</volume><fpage>5</fpage><pub-id pub-id-type="pmid">16620385</pub-id></citation></ref><ref id="pntd.0000375-Rothman1"><label>47</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Rothman</surname><given-names>KJ</given-names></name></person-group><year>1986</year><source>Modern Epidemiology</source><publisher-loc>Boston/Toronto</publisher-loc><publisher-name>Little, Brown and Company</publisher-name><fpage>320</fpage><lpage>326</lpage></citation></ref><ref id="pntd.0000375-Andersson1"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>T</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name><name><surname>Kallberg</surname><given-names>H</given-names></name><name><surname>Zdravkovic</surname><given-names>S</given-names></name><name><surname>Ahlbom</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>Calculating measures of biological interaction.</article-title><source>Eur J Epidemiol</source><volume>20</volume><fpage>575</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">16119429</pub-id></citation></ref><ref id="pntd.0000375-Hosmer1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hosmer</surname><given-names>DW</given-names></name><name><surname>Lemeshow</surname><given-names>S</given-names></name></person-group><year>1992</year><article-title>Confidence interval estimation of interaction.</article-title><source>Epidemiology</source><volume>3</volume><fpage>452</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">1391139</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p>This work was supported by PHS grants AI 053695 and T32 AI060546 from the NIAID, and D43 TW007123 from the FIC, National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 